Status:

UNKNOWN

Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

Lead Sponsor:

Medical University of Vienna

Conditions:

Reperfusion Injury

Vascular Complications

Eligibility:

MALE

18-40 years

Phase:

PHASE1

Brief Summary

The aim of the study is to investigate the effect of dapagliflozin or placebo on acetylcholine (Ach)- or nitroglycerin (GTN)-induced vasodilation of the forearm resistance vasculature, as determined b...

Detailed Description

The aim is to test the effect of dapagliflozin or placebo on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm is...

Eligibility Criteria

Inclusion

  • Healthy male subjects; 18 - 40 years of age
  • Body mass index between 18 and 27 kg/m2
  • Written informed consent
  • Normal findings in medical history
  • Non-smoking

Exclusion

  • Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
  • History of occlusive vascular diseases
  • History of vascular anomalies
  • History of coagulation disorders
  • History of diabetes mellitus (Type 1\&2) or pre-diabetes (i.e. HbA1c ≥ 5,7 %)
  • History of kidney disease
  • History of ketoacidosis
  • Impaired liver function (AST, ALT, gGT, bilirubin \>3 x ULN)
  • Impaired renal function (serum creatinine \> 1.3 mg/dl)
  • Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis
  • HIV-1/2-Ab, HbsAg or HCV-Ab positive serology
  • Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg
  • Known allergy against any test agent under study and/or lactose intolerance
  • Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol
  • Participation in another clinical trial during the preceding 3 weeks

Key Trial Info

Start Date :

February 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2023

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT05217654

Start Date

February 18 2022

End Date

August 1 2023

Last Update

February 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of Vienna

Vienna, Austria, 1090